Abstract Pulmonary Arterial Hypertension (PAH) is the progressive increase in mean
pulmonary arterial pressure (mPAP)(≥ 20 mmHg at rest). Current treatment strategies …

Idiopathic pulmonary arterial hypertension (PAH) is a fatal and progressive disease.
Sustained vasoconstriction due to pulmonary arterial smooth muscle cell (PASMC) …

Serotonin plays a key role in the development and maintenance of the pathobiology
associated with pulmonary arterial hypertension (PAH). Platelet‐driven and locally produced …

Abstract Objectives Systemic sclerosis (SSc) is a complex, autoimmune disease
characterized by multiple organ fibrosis and vasculopathy. Experimental and clinical …

Background The role of serotonin in pulmonary arterial hypertension has been extensively
studied in recent decades, with preclinical data strongly indicating involvement in disease …

Pulmonary arterial hypertension (PAH), defined as a mean pulmonary artery pressure
exceeding 20 mmHg with a pulmonary vascular resistance of 3 or more Wood units, is an …

Introduction Distal pulmonary arterial remodeling and elevated pulmonary vascular
resistance are characteristic of pulmonary arterial hypertension (PAH). Current approved …

The pathogenic mechanisms by which pulmonary arterial hypertension (PAH) develops and
progresses are complex and not fully elucidated. Considerable heterogeneity in disease …

Conclusion Tous ces essais thérapeutiques marquent un véritable tournant dans la
recherche des traitements de l'HTAP. Les traitements actuellement utilisés dans l'HTAP …

Background: Pulmonary hypertension (PH) is a multi-faceted disease characterised by
vascular remodelling and elevated pressure in the pulmonary arteries. Whilst targeted …